TG Therapeutics Stock Price is Rising as Q1 Revenues from BRIUMVI U.S. Have Exceeded Expectations

TG Therapeutics Financial Results for Q1 2024
TG Therapeutics, Inc. (TGTX) announced its financial results for the first quarter of 2024, along with recent company developments.

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “We were extremely pleased with the strong sales of just over $50 million in BRIUMVI U.S. net revenue for the first . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.